By KYIV. Nov 6 (Interfax-Ukraine) – JSC Lekhim (Kyiv) in 2022 saw its net profit to fall by 36.5% compared to 2021 – to UAH 247.308 million.
According to the company’s report in the information disclosure system of the National Securities and Stock Market Commission, its performance indicators will be reviewed by its shareholders at an extraordinary meeting on December 4.
In addition, the shareholders plan to make changes to the corporate governance system and re-elect head of the board Valeriy Pechaev to the position of head of the board of directors, deputy head of the board Tetiana Pechaeva to the position of chief executive officer, member of the board Olha Pechaeva to the position of executive director, members of the board Valentyna Mazuryk, Lesia Redkina, Liubov Lazko, Svitlana Pechaeva as directors of the joint-stock company.
Lekhim group of companies produces more than 200 types of medicines from almost all therapeutic groups, and the company registers more than 10 new drugs every year. Its products are exported to more than 35 countries around the world. One of the anti-tuberculosis drugs of Lekhim is prequalified by the WHO.
As reported, in 2023, Lekhim signed a sublicensing agreement with the Medicines Patent Pool (MPP) to release a generic version of the innovative Japanese antiviral drug Ensitrelvir produced by Shionogi, which can be used to treat COVID-19. Sublicensing agreements were signed by seven pharmaceutical companies, and Lekhim is the only Ukrainian pharmaceutical manufacturer among them. In addition, the agreement was signed by three generic pharmaceutical manufacturers from China, two companies from India and a company from Vietnam.
